OVERVIEW

Radiopharmaceuticals are reshaping precision oncology by coupling targeted biology with therapeutic radionuclides for selective tumor killing.

This meeting at AstraZeneca DISC, Cambridge, UK brings together industry and academic leaders to tackle discovery-to-development challenges, integrating insights from case studies, CMC and manufacturing, supply-chain resilience, and evolving regulatory expectations.

The programme will highlight design choices that influence efficacy and safety, spanning isotope selection, linker and vector engineering, and payload optimization. Attendees will gain practical insights into on drug design, radionuclide sourcing, and translation from concept to clinic.

Confirmed speakers are:

• Mark Fielding (AZ)
• Mike Hannay (Bicycle Tx)
• Matias Hert (Tetrakit, Univ Copenhagen)
• Sandra Hennig (Bayer)
• Jenny Karlsson (Bayer)
• Gemma Mudd (Bicycle Tx)
• Aimen Zlinti (Fusion)

More information to follow